BRENTUXIMAB VEDONTIN FOR SKIN INVOLVEMENT IN REFRACTORY DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS, INTERIM RESULTS OF A PHASE IIB OPEN-LABEL TRIAL

被引：7
|
作者：
Fernandez-Codina, A. [1 ,2 ,3 ]
Nevskaya, T. [1 ]
Pope, J. [1 ]
机构：
[1] Western Univ, Div Rheumatol, Med, London, ON, Canada
[2] Windsor Reg Hosp Ouellette Campus, Med, Windsor, ON, Canada
[3] Hosp Clin Barcelona, Syst Autoimmune Dis, Barcelona, Spain
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2021年 / 80卷
关键词：
D O I：
10.1136/annrheumdis-2021-eular.2115
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
OP0172
引用
收藏
页码：103 / 104
页数：2
相关论文
共 50 条
  • [31] Safety and Efficacy of Subcutaneous Tocilizumab in Early Systemic Sclerosis: Results from the Open-Label Period of a Phase 2 Randomized, Controlled Trial
    Khanna, Dinesh
    Denton, Christopher
    Spotswood, Helen
    Jahreis, Angelika
    van Laar, Jacob M.
    Burke, Laura
    Lin, Celia J. F.
    Pope, Janet E.
    Allanore, Yannick
    Mueller-Ladner, Ulf
    Siegel, Jeffrey
    Furst, Daniel E.
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [32] Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate)
    Khanna, Dinesh
    Denton, Christopher P.
    Lin, Celia J. F.
    van Laar, Jacob M.
    Frech, Tracy M.
    Anderson, Marina E.
    Baron, Murray
    Chung, Lorinda
    Fierlbeck, Gerhard
    Lakshminarayanan, Santhanam
    Allanore, Yannick
    Pope, Janet E.
    Riemekasten, Gabriela
    Steen, Virginia
    Mueller-Ladner, Ulf
    Spotswood, Helen
    Burke, Laura
    Siegel, Jeffrey
    Jahreis, Angelika
    Furst, Daniel E.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 (02) : 212 - 220
  • [33] SAFETY AND EFFICACY OF SUBCUTANEOUS TOCILIZUMAB IN EARLY SYSTEMIC SCLEROSIS: RESULTS FROM THE OPEN-LABEL PERIOD OF THE FASSCINATE TRIAL
    Khanna, D.
    Denton, C. P.
    Jahreis, A.
    van Laar, J. M.
    Burke, L.
    Spotswood, H.
    Lin, C. J.
    Pope, J. E.
    Allanore, Y.
    Muller-Ladner, U.
    Siegel, J.
    Furst, D. E.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 531 - 532
  • [34] Adalimumab therapy for refractory uveitis: results of a multicentre, open-label, prospective trial
    Suhler, Eric B.
    Lowder, Careen Y.
    Goldstein, Debra A.
    Giles, Tracy
    Lauer, Andreas K.
    Kurz, Paul A.
    Pasadhika, Sirichai
    Lee, Shelly T.
    de Saint Sardos, Alexandre
    Butler, Nicholas J.
    Tessler, Howard H.
    Smith, Justine R.
    Rosenbaum, James T.
    BRITISH JOURNAL OF OPHTHALMOLOGY, 2013, 97 (04) : 481 - 486
  • [35] Dabigatran Etexilate in Children with Venous Thromboembolism: Results of the Open-Label, Phase IIb/III, Randomized Diversity Clinical Trial
    Halton, Jacqueline
    Brandao, Leonardo R.
    Luciani, Matteo
    Bomgaars, Lisa
    Chalmers, Elizabeth
    Mitchell, Lesley
    Nurmeev, Ildar
    Sharathkumar, Anjali
    Svirin, Pavel
    Gorbatikov, Kirill
    Tartakovsky, Igor
    Simetzberger, Monika
    Huang, Fenglei
    Sun, Zhichao
    Kreuzer, Jorg
    Gropper, Savion
    Brueckmann, Martina
    Albisetti, Manuela
    BLOOD, 2020, 136
  • [36] Comment on: A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis: reply
    Derk, Chris T.
    Grace, Elizabeth
    Shenin, Max
    Naik, Manisha
    Schulz, Steffan
    Xiong, Wen
    RHEUMATOLOGY, 2010, 49 (08) : 1608 - 1608
  • [37] Two years follow-up of an open-label pilot study of treatment with rituximab in patients with early diffuse cutaneous systemic sclerosis
    Melsens, Karin
    Vandecasteele, Els
    Deschepper, Ellen
    Badot, Valerie
    Blockmans, Daniel
    Brusselle, Guy
    De Langhe, Ellen
    De Pauw, Michel
    Debusschere, Claire
    Decuman, Saskia
    Deroo, Liselotte
    Houssiau, Frederic
    Lenaerts, Jan
    Piette, Yves
    Thevissen, Kristof
    Vanthuyne, Marie
    Westhovens, Rene
    Wijnant, Sara
    De Keyser, Filip
    Smith, Vanessa
    ACTA CLINICA BELGICA, 2018, 73 (02) : 119 - 125
  • [38] Open-label Phase II trial of ozoralizumab produces promising results
    Fitzpatrick, Sean
    IMMUNOTHERAPY, 2012, 4 (08) : 760 - 760
  • [39] Results of an open-label multicenter phase 2 trial of lenalidomide monotherapy in refractory mycosis fungoides and Sezary syndrome
    Querfeld, Christiane
    Rosen, Steven T.
    Guitart, Joan
    Duvic, Madeleine
    Kim, Youn H.
    Dusza, Stephen W.
    Kuzel, Timothy M.
    BLOOD, 2014, 123 (08) : 1159 - 1166
  • [40] Midostaurin in patients with indolent systemic mastocytosis: An open-label phase 2 trial
    van Anrooij, Bjorn
    Elberink, Joanne N. G. Oude
    Span, Lambert F. R.
    de Monchy, Jan G. R.
    Rosati, Stefano
    Mulder, Andre B.
    Kluin-Nelemans, Johanna C.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2018, 142 (03) : 1006 - +
12345